Determination of adherence to treatment of Multiple Sclerosis patients

Ahsen Taştan Gürkan; Afitap Özdelikara

Makale detayları

Determination of adherence to treatment of Multiple Sclerosis patients

Yazarlar:

Ahsen Taştan Gürkan | Afitap Özdelikara

Yayıncı:

Mersin University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Mersin Üniversitesi Sağlık Bilimleri Dergisi Vol.17 Issue 1, pp.9-19

Belge Tipi:

Makale

Yayın Tarihi:

4/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001315091

pISSN:

1308-0830

Anahtar kelimeler:

Özet:

 Aim: The basic approach in chronic disease care includes ensuring compliance with treatment. Ensuring adherence to treatment is important in terms of increasing the quality of life of individuals. Multiple Sclerosis MS, a chronic disease, is a disease in which adherence to treatment is extremely important for a successful treatment process. This study was conducted as a descriptive study to determine treatment compliance in MS. Method: The population of the study consisted of 164 MS patients who participated to the study between April 2020 and February 2021. Data were collected online using the Introductory Information Form, which determines the sociodemographic and disease-related characteristics of the individuals, and the Multiple Sclerosis Treatment Adherence Questionnaire MS-TAQ. Percentage and mean calculations, Kruskal Wallis test and Spearman correlation analysis were used in the analysis of the data. Results: It was determined that 72.6 of the participants were female, 50.6 were between the ages of 30-41, 66.5 were married, 48.2 did not know the type of MS, 38.4 had Relapsing Progressive MS, 20.1 applied Interferon Beta 1a subcutaneous injection treatment. It was determined that the barriers sub-dimension mean score was 9.728.17, the side effects sub-dimension 9.2111.46, and the Coping Strategies sub-dimension 1.091.87. Participants reported that injection side effects were a very important obstacle, that they always experienced chills, flicker, headaches or flu-like symptoms after treatment, and that taking medication to reduce pain before administering the treatment was their most common coping strategy. Conclusion: Despite the high compliance of MS patients with treatment, it stands out as a condition that should be supported. On the other hand, the most difficult situation for patients to adapt during the treatment process is that they could not adequately develop strategies to cope with the symptoms that occur after the treatment.

 Aim: The basic approach in chronic disease care includes ensuring compliance with treatment. Ensuring adherence to treatment is important in terms of increasing the quality of life of individuals. Multiple Sclerosis MS, a chronic disease, is a disease in which adherence to treatment is extremely important for a successful treatment process. This study was conducted as a descriptive study to determine treatment compliance in MS. Method: The population of the study consisted of 164 MS patients who participated to the study between April 2020 and February 2021. Data were collected online using the Introductory Information Form, which determines the sociodemographic and disease-related characteristics of the individuals, and the Multiple Sclerosis Treatment Adherence Questionnaire MS-TAQ. Percentage and mean calculations, Kruskal Wallis test and Spearman correlation analysis were used in the analysis of the data. Results: It was determined that 72.6 of the participants were female, 50.6 were between the ages of 30-41, 66.5 were married, 48.2 did not know the type of MS, 38.4 had Relapsing Progressive MS, 20.1 applied Interferon Beta 1a subcutaneous injection treatment. It was determined that the barriers sub-dimension mean score was 9.728.17, the side effects sub-dimension 9.2111.46, and the Coping Strategies sub-dimension 1.091.87. Participants reported that injection side effects were a very important obstacle, that they always experienced chills, flicker, headaches or flu-like symptoms after treatment, and that taking medication to reduce pain before administering the treatment was their most common coping strategy. Conclusion: Despite the high compliance of MS patients with treatment, it stands out as a condition that should be supported. On the other hand, the most difficult situation for patients to adapt during the treatment process is that they could not adequately develop strategies to cope with the symptoms that occur after the treatment.

 Aim: The basic approach in chronic disease care includes ensuring compliance with treatment. Ensuring adherence to treatment is important in terms of increasing the quality of life of individuals. Multiple Sclerosis MS, a chronic disease, is a disease in which adherence to treatment is extremely important for a successful treatment process. This study was conducted as a descriptive study to determine treatment compliance in MS. Method: The population of the study consisted of 164 MS patients who participated to the study between April 2020 and February 2021. Data were collected online using the Introductory Information Form, which determines the sociodemographic and disease-related characteristics of the individuals, and the Multiple Sclerosis Treatment Adherence Questionnaire MS-TAQ. Percentage and mean calculations, Kruskal Wallis test and Spearman correlation analysis were used in the analysis of the data. Results: It was determined that 72.6 of the participants were female, 50.6 were between the ages of 30-41, 66.5 were married, 48.2 did not know the type of MS, 38.4 had Relapsing Progressive MS, 20.1 applied Interferon Beta 1a subcutaneous injection treatment. It was determined that the barriers sub-dimension mean score was 9.728.17, the side effects sub-dimension 9.2111.46, and the Coping Strategies sub-dimension 1.091.87. Participants reported that injection side effects were a very important obstacle, that they always experienced chills, flicker, headaches or flu-like symptoms after treatment, and that taking medication to reduce pain before administering the treatment was their most common coping strategy. Conclusion: Despite the high compliance of MS patients with treatment, it stands out as a condition that should be supported. On the other hand, the most difficult situation for patients to adapt during the treatment process is that they could not adequately develop strategies to cope with the symptoms that occur after the treatment.

 Amaç: Kronik hastalık bakımında temel yaklaşım tedaviye uyumun sağlanmasını içermektedir. Tedaviye uyumun sağlanması bireylerin yaşam kalitesini artırmak bakımından önem arz etmektedir. Kronik bir hastalık olan Multiple Skleroz MS, başarılı bir tedavi süreci için tedaviye uyumun son derece önemli olduğu bir hastalıktır. Bu araştırma, MSte tedaviye uyumunun belirlenmesi amacıyla tanımlayıcı olarak yapılmıştır. Yöntem: Araştırmanın evrenini Nisan 2020-Şubat 2021 tarihleri arasında çalışmaya katılan 164 MS hastası oluşturmuştur. Veriler bireylerin sosyodemografik ve hastalığa ilişkin özellikleri belirleyen Tanıtıcı Bilgi Formu ve Multiple Skleroz Tedaviye Uyum Anketi MS-TAQ kullanılarak çevrimiçi toplanmıştır. Verilerin analizinde yüzdelik ve ortalama hesaplamaları, Kruskal Wallis testi ve Spearman korelasyon analizi kullanılmıştır. Bulgular: Katılımcıların 72.6sının kadın, 50.6sının 30-41 yaş aralığında olduğu, 66.5inin evli, 48.2sinin MS tipini bilmediği, 38.4ünün Relapsing Progresif MS tipine sahip olduğu, 20.1inin ise İnterferon Beta 1a cilt altı enjeksiyon tedavisi uyguladığı belirlenmiştir. Engeller alt boyut ortalama puanının 9.728.17, yan etkiler alt boyutunun 9.2111.46, başetme stratejileri alt boyutunun 1.091.87 olduğu belirlenmiştir. Katılımcılar enjeksiyon yan etkilerinin çok önemli bir engel olduğunu, tedavi sonrasında üşüme, titreme, baş ağrısı ya da grip benzeri semptomları her zaman yaşadıklarını ve tedaviyi uygulamadan önce ağrıyı azaltmak için ilaç alma yöntemini en çok kullandıkları başetme stratejisi olarak bildirmişlerdir. Sonuç: MS hastalarının tedavi uyumu yüksek olmasına rağmen desteklenmesi gereken bir durum olarak öne çıkmaktadır. Öte yandan tedavi sürecinde hastaların uyumunu en çok güçleştiren durum tedavi sonrası oluşan semptomlarla başetme stratejilerini yeterince geliştirememiş olmalarıdır.

Makale detayları

Determination of adherence to treatment of Multiple Sclerosis patients

Yazarlar:

Ahsen Taştan Gürkan | Afitap Özdelikara

Yayıncı:

Mersin University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Mersin Üniversitesi Sağlık Bilimleri Dergisi Vol.17 Issue 1, pp.9-19

Belge Tipi:

Makale

Yayın Tarihi:

4/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001315091

pISSN:

1308-0830

Treatment compliance

Multiple Sclerosis

chronic disease

nursingTedaviye uyum

Multiple skleroz

kronik hastalık

hemşirelik

Sayı

Makale detayları

Yazarlar: Ahsen Taştan Gürkan | Afitap Özdelikara

Yayıncı: Mersin University

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: Mersin Üniversitesi Sağlık Bilimleri Dergisi Vol.17 Issue 1, pp.9-19

Belge Tipi: Makale

Yayın Tarihi: 4/2024

Belge Dili: Türkçe

Document ID (Org No.): 2001315091

pISSN: 1308-0830

Sayı

Yazarlar:

Ahsen Taştan Gürkan | Afitap Özdelikara

Yayıncı:

Mersin University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Mersin Üniversitesi Sağlık Bilimleri Dergisi Vol.17 Issue 1, pp.9-19

Belge Tipi:

Makale

Yayın Tarihi:

4/2024

Belge Dili:

Türkçe

Document ID (Org No.):

2001315091

pISSN:

1308-0830